These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 6689994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC, Nissenkorn I, Palmieri GM, Ikard M, Moinuddin M, Soloway MS.
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM, Kim H, Wang JC, Tobin MS, Wax SH.
    Prostate; 1983 Feb; 4(4):397-405. PubMed ID: 6191318
    [Abstract] [Full Text] [Related]

  • 8. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K, Imai K, Yamanaka H, Tomaru Y, Kitaura K.
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [Abstract] [Full Text] [Related]

  • 9. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K, Aoyagi K.
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [Abstract] [Full Text] [Related]

  • 10. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S, Rinsho K.
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract] [Full Text] [Related]

  • 11. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC, Fellows GJ.
    Br J Urol; 1977 Jan; 49(7):711-6. PubMed ID: 597712
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Urinary hydroxyproline and prognosis in human breast cancer.
    Grant CS, Hoare SA, Millis RR, Hayward JL, Wang DY.
    Br J Surg; 1984 Feb; 71(2):105-8. PubMed ID: 6692099
    [Abstract] [Full Text] [Related]

  • 14. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
    Mundy AR.
    Br J Urol; 1979 Dec; 51(6):570-4. PubMed ID: 534843
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J, Cárcamo P, Martínez ME, Martínez-Piñeiro JA.
    Actas Urol Esp; 1983 Dec; 7(3):199-204. PubMed ID: 6624563
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
    Heller W, Harzmann R, Bichler KH, Schmidt K.
    Curr Probl Clin Biochem; 1979 Dec; (9):249-56. PubMed ID: 446076
    [Abstract] [Full Text] [Related]

  • 19. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE, Pachas WN, Pinals RS, Krant MJ.
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.